XENETIC BIOSCIENCES INC (XBIO) Fundamental Analysis & Valuation

NASDAQ:XBIO • US9840156023

Current stock price

2.77 USD
-0.22 (-7.36%)
Last:

This XBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. XBIO Profitability Analysis

1.1 Basic Checks

  • XBIO had negative earnings in the past year.
  • In the past year XBIO has reported a negative cash flow from operations.
  • In the past 5 years XBIO always reported negative net income.
  • XBIO had a negative operating cash flow in each of the past 5 years.
XBIO Yearly Net Income VS EBIT VS OCF VS FCFXBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10M -20M -30M -40M -50M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -32.05%, XBIO is in the better half of the industry, outperforming 63.20% of the companies in the same industry.
  • XBIO has a Return On Equity of -36.25%. This is in the better half of the industry: XBIO outperforms 71.10% of its industry peers.
Industry RankSector Rank
ROA -32.05%
ROE -36.25%
ROIC N/A
ROA(3y)-42.81%
ROA(5y)-40.29%
ROE(3y)-48.13%
ROE(5y)-44.62%
ROIC(3y)N/A
ROIC(5y)N/A
XBIO Yearly ROA, ROE, ROICXBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for XBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIO Yearly Profit, Operating, Gross MarginsXBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20K -40K -60K -80K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. XBIO Health Analysis

2.1 Basic Checks

  • XBIO has more shares outstanding than it did 1 year ago.
  • XBIO has more shares outstanding than it did 5 years ago.
  • XBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XBIO Yearly Shares OutstandingXBIO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M 2M
XBIO Yearly Total Debt VS Total AssetsXBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

2.2 Solvency

  • XBIO has an Altman-Z score of -28.96. This is a bad value and indicates that XBIO is not financially healthy and even has some risk of bankruptcy.
  • XBIO has a Altman-Z score of -28.96. This is amonst the worse of the industry: XBIO underperforms 87.86% of its industry peers.
  • There is no outstanding debt for XBIO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -28.96
ROIC/WACCN/A
WACCN/A
XBIO Yearly LT Debt VS Equity VS FCFXBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M -5M 10M 15M

2.3 Liquidity

  • XBIO has a Current Ratio of 8.32. This indicates that XBIO is financially healthy and has no problem in meeting its short term obligations.
  • XBIO has a Current ratio of 8.32. This is in the better half of the industry: XBIO outperforms 74.18% of its industry peers.
  • XBIO has a Quick Ratio of 8.32. This indicates that XBIO is financially healthy and has no problem in meeting its short term obligations.
  • XBIO's Quick ratio of 8.32 is fine compared to the rest of the industry. XBIO outperforms 74.18% of its industry peers.
Industry RankSector Rank
Current Ratio 8.32
Quick Ratio 8.32
XBIO Yearly Current Assets VS Current LiabilitesXBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. XBIO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 36.62% over the past year.
  • The Revenue has grown by 19.05% in the past year. This is quite good.
  • Measured over the past years, XBIO shows a very strong growth in Revenue. The Revenue has been growing by 46.57% on average per year.
EPS 1Y (TTM)36.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.14%
Revenue 1Y (TTM)19.05%
Revenue growth 3Y20.29%
Revenue growth 5Y46.57%
Sales Q2Q%18.26%

3.2 Future

  • Based on estimates for the next years, XBIO will show a very strong growth in Earnings Per Share. The EPS will grow by 35.40% on average per year.
  • Based on estimates for the next years, XBIO will show a decrease in Revenue. The Revenue will decrease by 0.00% on average per year.
EPS Next Y-62.75%
EPS Next 2Y35.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year20%
Revenue Next 2Y0%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
XBIO Yearly Revenue VS EstimatesXBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M
XBIO Yearly EPS VS EstimatesXBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2019 2020 2021 2022 2023 2024 2025 2026 2027 -50 -100 -150

More info and screens

Find the best growth stocksShow best growing peers

1

4. XBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • XBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year XBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIO Price Earnings VS Forward Price EarningsXBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIO Per share dataXBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as XBIO's earnings are expected to grow with 35.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.4%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. XBIO Dividend Analysis

5.1 Amount

  • No dividends for XBIO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

XBIO Fundamentals: All Metrics, Ratios and Statistics

XENETIC BIOSCIENCES INC

NASDAQ:XBIO (3/26/2026, 1:45:33 PM)

2.77

-0.22 (-7.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-16
Earnings (Next)05-11
Inst Owners10.28%
Inst Owner Change293.53%
Ins Owners0.82%
Ins Owner Change0%
Market Cap6.34M
Revenue(TTM)2.98M
Net Income(TTM)-2.68M
Analysts43.33
Price TargetN/A
Short Float %2.44%
Short Ratio2.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)34.35%
Min Revenue beat(2)8.88%
Max Revenue beat(2)59.82%
Revenue beat(4)2
Avg Revenue beat(4)11.47%
Min Revenue beat(4)-13.19%
Max Revenue beat(4)59.82%
Revenue beat(8)4
Avg Revenue beat(8)26.41%
Revenue beat(12)7
Avg Revenue beat(12)26.91%
Revenue beat(16)11
Avg Revenue beat(16)31.97%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.13
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 0.86
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-3.39
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS1.3
BVpS3.23
TBVpS3.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -32.05%
ROE -36.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.81%
ROA(5y)-40.29%
ROE(3y)-48.13%
ROE(5y)-44.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.32
Quick Ratio 8.32
Altman-Z -28.96
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.14%
EPS Next Y-62.75%
EPS Next 2Y35.4%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.05%
Revenue growth 3Y20.29%
Revenue growth 5Y46.57%
Sales Q2Q%18.26%
Revenue Next Year20%
Revenue Next 2Y0%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-76.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y18.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.84%
OCF growth 3YN/A
OCF growth 5YN/A

XENETIC BIOSCIENCES INC / XBIO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for XENETIC BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 3 / 10 to XBIO.


What is the valuation status for XBIO stock?

ChartMill assigns a valuation rating of 1 / 10 to XENETIC BIOSCIENCES INC (XBIO). This can be considered as Overvalued.


How profitable is XENETIC BIOSCIENCES INC (XBIO) stock?

XENETIC BIOSCIENCES INC (XBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for XBIO stock?

The financial health rating of XENETIC BIOSCIENCES INC (XBIO) is 6 / 10.